Primecap Management Co. CA Boosts Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Primecap Management Co. CA grew its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 21.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,498,030 shares of the company's stock after purchasing an additional 265,690 shares during the period. Primecap Management Co. CA owned approximately 2.11% of Zentalis Pharmaceuticals worth $5,513,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZNTL. ProShare Advisors LLC grew its holdings in shares of Zentalis Pharmaceuticals by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 15,436 shares of the company's stock valued at $243,000 after purchasing an additional 1,274 shares during the last quarter. Values First Advisors Inc. increased its position in Zentalis Pharmaceuticals by 5.4% during the second quarter. Values First Advisors Inc. now owns 74,925 shares of the company's stock valued at $306,000 after acquiring an additional 3,859 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company's stock worth $50,000 after acquiring an additional 5,333 shares during the period. Carson Advisory Inc. raised its stake in Zentalis Pharmaceuticals by 55.8% during the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company's stock worth $90,000 after acquiring an additional 8,800 shares during the period. Finally, Anfield Capital Management LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth about $40,000.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ZNTL shares. Oppenheimer restated an "outperform" rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Wedbush upgraded shares of Zentalis Pharmaceuticals from an "underperform" rating to a "neutral" rating and set a $4.00 target price for the company in a report on Monday, August 12th. Guggenheim lowered their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, November 15th. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Zentalis Pharmaceuticals currently has an average rating of "Hold" and an average price target of $10.00.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL traded up $0.05 on Friday, hitting $3.23. The company had a trading volume of 1,171,471 shares, compared to its average volume of 1,618,453. The company has a market capitalization of $230.17 million, a PE ratio of -1.30 and a beta of 1.74. Zentalis Pharmaceuticals, Inc. has a 12-month low of $2.66 and a 12-month high of $18.07. The company's fifty day moving average price is $3.42 and its 200-day moving average price is $5.18.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. On average, sell-side analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.